TriSalus Life Sciences (NASDAQ:TLSI – Free Report) and Nevro (NYSE:NVRO – Free Report) are both small healthcare companies, but which is the better company? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, and profitability.
profitability
This table compares the net margins, return on equity and return on assets of TriSalus Life Sciences and Nevro.
| Net margins | Return on equity | Return on total assets | |
| TriSalus Biosciences | N/A | N/A | -221.65% |
| Neuro | -19.17% | -27.48% | -13.40% |
Volatility and risk
TriSalus Life Sciences has a beta of 0.49, meaning the company’s share price is 51% less volatile than the S&P 500. For comparison, Nevro has a beta of 0.91, meaning the company’s share price is 9% less volatile than the S&P 500.
Analyst ratings
This is a summary of the latest ratings and recommendations for TriSalus Life Sciences and Nevro from MarketBeat.com.
| Sales ratings | Keep ratings | Buy reviews | Strong buy recommendations | Evaluation result | |
| TriSalus Biosciences | 0 | 0 | 3 | 0 | 3.00 |
| Neuro | 3 | 11 | 0 | 0 | 1.79 |
TriSalus Life Sciences currently has a consensus price target of $13.33, suggesting a potential upside of 135.57%. Nevro has a consensus price target of $10.63, suggesting a potential upside of 76.81%. Given TriSalus Life Sciences’ better consensus rating and higher possible upside, analysts clearly believe that TriSalus Life Sciences is cheaper than Nevro.
Insider and institutional ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. By comparison, 95.5% of Nevro shares are held by institutional investors. 76.2% of TriSalus Life Sciences shares are held by company insiders. By comparison, 3.2% of Nevro shares are held by company insiders. A strong institutional share is an indication that large asset managers, hedge funds and foundations believe a company will outperform the market over the long term.
Yield and valuation
This table compares the gross revenue, earnings per share and valuation of TriSalus Life Sciences and Nevro.
| Gross sales | Price/sales ratio | Net income | Earnings per share | Price-earnings ratio | |
| TriSalus Biosciences | 21.98 million US dollars | 6.99 | -59.04 million US dollars | N/A | N/A |
| Neuro | 426.10 million US dollars | 0.52 | -92.21 million US dollars | ($2.29) | -2.62 |
TriSalus Life Sciences has higher profits but lower revenues than Nevro.
Summary
TriSalus Life Sciences beats Nevro on 8 of the 12 factors compared between the two stocks.
About TriSalus Life Sciences
(Get free report)
TriSalus Life Sciences, Inc., a medical device company, discovers, develops and commercializes drug delivery technologies and immuno-oncology therapeutics for the treatment of liver and pancreatic cancer. The Company offers pressure-controlled drug delivery systems, such as the TriNav infusion system used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases, and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trials, for locally advanced pancreatic cancer. It is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trials for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, caregivers, value analysis committee members, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About Nevro
(Get free report)
Nevro Corp., a medical device company, is engaged in providing products to patients with chronic pain in the United States and internationally. The Company offers the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for treating chronic back and leg pain using paresthesia-free 10 kHz therapy, and the Senza II and Senza Omnia SCS IPG systems. It also offers the Senza HFX iQ platform, which includes the HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as the HFX app, patient remote, and wireless trial system; and offers sacroiliac joint fusion devices under the NevroV1, NevroFix, and NevroPro brands. In addition, the Company offers superior surgical and percutaneous leads. It sells its products through its direct sales force and a network of sales representatives and independent dealers. The company was founded in 2006 and is headquartered in Redwood City, California.
Get daily news and reviews for TriSalus Life Sciences – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TriSalus Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
